AN2 Therapeutics, Inc.
epetraborole
M. abscessus complex lung disease
Countdown
358days
Phase 2 readout · ~ Jun 30, 2027 estimated
What's at stake
Phase 2 trial results for epetraborole in M. abscessus complex lung disease are due ~ Jun 30, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“The Company expects to initiate enrollment in the first quarter of 2026 and report topline results in late 2027.”